3 terminated. 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
Follow Attention Deficit and Disruptive Behavior Disorders: new trials by email Literature Review of Attention Deficit and Disruptive Behavior Disorders trials Research Report on Attention Deficit and Disruptive Behavior Disorders
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vitamin D as a Therapeutic Adjunct in the Stimulant Treatment of ADHD: a Proof-of-concept Tele-health Study of Stimulant-induced Improvement in Neurocognitive Functioning. Calcitriol, Placebo - ADHD | Phase 1 | Terminated | Yale University | 3 | 2020-08-05 | 2024-02-07 |
| A Phase 1 Study to Investigate the Safety, Tolerance, Food Effect, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Extended Release Formulations of Centanafadine (CTN) in Young Healthy Subjects CTN SR1, CTN XR1, CTN XR2 - Adult Attention-deficit Hyperactivity Disorder (ADHD) | Phase 1 | Terminated | Otsuka Pharmaceutical Development & Commercialization, Inc. | 16 | 2015-12-01 | 2022-02-18 |
| Safety, Tolerability, and Pharmacokinetics of Multiple Rising Doses of TAK-137 in Adults With Attention-Deficit/Hyperactivity Disorder. TAK-137, TAK-137 Placebo - Attention-Deficit/Hyperactivity Disorder | Phase 1 | Terminated | Takeda | 47 | 2014-06-01 | 2016-07-11 |
Attention Deficit Disorder with Hyperactivity (3)
Mental Disorders (3) · Neurodevelopmental Disorders (3)
Calcitriol (1) · TAK-137 (1)
Otsuka Pharmaceutical Development & Commercialization, Inc. (1) · Takeda (1) · Yale University (1)
United States (2) · Australia (1)
Marc Potenza, MD (1)